Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of oxymatrine and derivatives to prepare medicines treating aseptic pustular dermatosis

A derivative, the technology of matrine, applied in the field of medicine, can solve the problems of unsatisfactory treatment effect, complex etiology and easy recurrence of aseptic pustular skin disease

Active Publication Date: 2016-02-10
施惠娟
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Drug therapy combined with local treatment: (1) Glucocorticoid: has a good therapeutic effect, but it is easy to relapse after stopping the drug
[0004] Due to the complex etiology of aseptic pustular dermatosis, although there are many treatment methods, they all have their limitations and adverse reactions, and the treatment effect is not very satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Comparison of Acute Toxic Effects of Oxymatrine on Mice

[0024] Kunming mice were randomly divided into a normal control group and a test drug group, with ten mice in each group, half male and half male. In addition to the normal control group, the test drug group was injected intraperitoneally (ip) with a large dose of oxymatrine once, observed continuously for 7 days, and recorded the death time and number of animals.

[0025] The results showed that when the dose of oxymatrine was 950mg / kg, it had great toxicity, and 9 out of 10 mice died.

[0026] Comparison of acute toxic effects of epioxymatrine, glycyrrhizic acid and their combination (ip once) on mice

[0027] group Dose (mg / kg) Deaths / Total normal control group 0 0 / 10 bitter 950 9 / 10

[0028] Remarks: "Bitter": means oxymatrine.

Embodiment 2

[0030] Clinical observation of oxymatrine in treating subcorneal impetigo

[0031] 1 Materials and methods

[0032] 1.1 Clinical data The clinical diagnosis was consistent with subcorneal impetigo in 3 patients, 1 male and 2 female, aged 24-38 years.

[0033] 1.2 Treatment method Intravenous infusion of oxymatrine injection 0.6g100ml / d; all 8 weeks as a course of treatment, after the course of treatment is over, the curative effect will be judged.

[0034] 1.3. Clinical recovery means that the skin lesions have disappeared by more than 90%; markedly effective means that the skin lesions have disappeared by 60% to 89%; progress means that the skin lesions have disappeared by 20% to 59%; ineffective means that the skin lesions have disappeared by less than 20%. The effective rate is calculated by clinical recovery plus marked effect.

[0035] 1.4 Safety evaluation Check blood and urine routine and biochemical routine (including liver and kidney function, blood sugar, electr...

Embodiment 3

[0041] Oxymatrine 600mg

[0042] NaCl0.9g

[0043] Appropriate amount of water for injection

[0044] 100ml each

[0045] Take NaCl, stir and dissolve with water for injection, then add oxymatrine, dissolve completely while continuing to stir, add water for injection to the total amount, filter until clear, seal in a jar, and sterilize to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of pharmaceutically-acceptable forms and derivatives of oxymatrines(oxymatrine and matrine) to prepare medicines treating aseptic pustular dermatosis(such as impetigo herpetiformis, acrodermatitis continua, palmoplantar pustulosis, subcorneal pustule dermatosis, and eosinophilic pustular folliculitis).

Description

technical field [0001] The invention belongs to the field of medicine and relates to the application of matrine and its derivatives in the preparation of medicines for treating aseptic pustular dermatosis. The medicine is matrine (oxymatrine, matrine, isomatrine) or a pharmaceutically acceptable form or derivative thereof and a medicine box containing the medicine. Background technique [0002] Aseptic pustular dermatoses include impetigo herpetiformis, acrodermatitis continuum, palmoplantar impetigo, subcorneal impetigo, and eosinophilic pustular folliculitis. The pathological changes were all characterized by the infiltration of neutrophils in the epidermis and the formation of Kogoj's cavernous pustules. The etiology and pathogenesis of aseptic pustular dermatosis are still unclear. (1) Infection factors: related to purulent infection, bacterial and viral infection; (2) Endocrine disorders and metabolic disorders: such as continuous fingertip dermatitis aggravated durin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P17/00A61P29/00
Inventor 施惠娟
Owner 施惠娟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com